THESIS CHECK: "THESE 10 PRECONCEPTIONS ABOUT OBESITY AND THE WEIGHT LOSS INJECTION ARE QUESTIONABLE"
In its "Thesencheck" (Theses Check) video series, the University of Tübingen has now taken up the topic of obesity. Watch now the full video on YouTube.
In its "Thesencheck" (Theses Check) video series, the University of Tübingen has now taken up the topic of obesity. The treatment of severely overweight individuals with the active ingredient semaglutide is currently a much-discussed topic. In the video, DZD speaker Prof. Dr. Andreas Birkenfeld, Medical Director of the Clinic for Diabetology, Endocrinology and Nephrology at the University Hospital of Tübingen, provides facts and background information in order to deal more objectively with theses and prejudices about obesity and its medication.
Birkenfeld is a diabetologist and endocrinologist whose daily work focuses on the treatment of obesity and type 2 diabetes. He also conducts research on obesity and how it can be treated better and more long-term.
In this context, he has participated in studies on semaglutide, the substance that has recently been launched in Germany in the form of the so-called "weight loss injection" for people with obesity under the drug name Wegovy. For people with type 2 diabetes, it has been available in lower doses under the name Ozempic for somewhat longer.
See the full video on YouTube.
See DZD News for more information.